TO

Toku

2 known investors

tokueyes.com ↗

Toku develops AI models that analyze retinal images to assess health conditions, including biological age (BioAge), cardiovascular risk (CLAiR), and chronic kidney disease risk in diabetic patients (MyKidneyAI). Its products, trained on a large dataset of retinal images linked to medical records, are aimed at healthcare providers using retinal cameras for early, non-invasive diagnosis.

Investors · 2

IC

Icehouse VenturesAuckland · $120K – $2.4M

OU

Outset Ventures$100K – $10M